Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christina Kalpadakis

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Leukemia & Lymphoma|January 28, 2012
Autoimmune hemolytic anemia and autoimmune thrombocytopenia at diagnosis and during follow-up of Hodgkin lymphomaMaria Dimou, Maria K Angelopoulou, Gerassimos A Pangalis, et al.
The Oncologist|January 28, 2012
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of careTheodoros P Vassilakopoulos, Gerassimos A Pangalis, Andreas Katsigiannis, et al.
Hematological Oncology|June 9, 2018
Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysisPanagiotis Tsirigotis, Theodoros Vassilakopoulos, Ioannis Batsis, et al.
Hematological Oncology|February 21, 2017
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experienceMaria K Angelopoulou, Theodoros P Vassilakopoulos, Ioannis Batsis, et al.
Hematological Oncology|February 14, 2021
Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomasMaria Dimou, Sotirios G Papageorgiou, Niki Stavroyianni, et al.
The Journal of Pathology|November 29, 2018
Disease-biased and shared characteristics of the immunoglobulin gene repertoires in marginal zone B cell lymphoproliferationsAliki Xochelli, Vasilis Bikos, Eleftheria Polychronidou, et al.
Annals of Hematology|February 1, 2021
Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategiesTheodoros P Vassilakopoulos, Sotirios G Papageorgiou, Maria K Angelopoulou, et al.
In Vivo (Athens, Greece)|April 28, 2022
Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell LymphomaStamatis J Karakatsanis, Maria Bouzani, Argyris Symeonidis, et al.
Blood Advances|May 27, 2026
Integrated multi-omic profiling reveals two distinct splenic marginal zone lymphoma subgroups with prognostic relevanceHelen Parker, Amatta Mirandari, Ben Stevens, et al.
The Oncologist|April 19, 2021
Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOPTheodoros P Vassilakopoulos, Michail Michail, Sotirios Papageorgiou, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Leukemia & Lymphoma|January 28, 2012
Autoimmune hemolytic anemia and autoimmune thrombocytopenia at diagnosis and during follow-up of Hodgkin lymphomaMaria Dimou, Maria K Angelopoulou, Gerassimos A Pangalis, et al.
The Oncologist|January 28, 2012
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of careTheodoros P Vassilakopoulos, Gerassimos A Pangalis, Andreas Katsigiannis, et al.
Hematological Oncology|June 9, 2018
Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysisPanagiotis Tsirigotis, Theodoros Vassilakopoulos, Ioannis Batsis, et al.
Hematological Oncology|February 21, 2017
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experienceMaria K Angelopoulou, Theodoros P Vassilakopoulos, Ioannis Batsis, et al.
Hematological Oncology|February 14, 2021
Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomasMaria Dimou, Sotirios G Papageorgiou, Niki Stavroyianni, et al.
The Journal of Pathology|November 29, 2018
Disease-biased and shared characteristics of the immunoglobulin gene repertoires in marginal zone B cell lymphoproliferationsAliki Xochelli, Vasilis Bikos, Eleftheria Polychronidou, et al.
Annals of Hematology|February 1, 2021
Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategiesTheodoros P Vassilakopoulos, Sotirios G Papageorgiou, Maria K Angelopoulou, et al.
In Vivo (Athens, Greece)|April 28, 2022
Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell LymphomaStamatis J Karakatsanis, Maria Bouzani, Argyris Symeonidis, et al.
Blood Advances|May 27, 2026
Integrated multi-omic profiling reveals two distinct splenic marginal zone lymphoma subgroups with prognostic relevanceHelen Parker, Amatta Mirandari, Ben Stevens, et al.
The Oncologist|April 19, 2021
Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOPTheodoros P Vassilakopoulos, Michail Michail, Sotirios Papageorgiou, et al.
Pageof 6